Division of General Internal Medicine, University of California San Francisco.
University of Illinois at Chicago College of Pharmacy, Chicago, IL.
J Manag Care Spec Pharm. 2022 Jan;28(1):119-124. doi: 10.18553/jmcp.2022.28.1.119.
Funding for this summary was contributed by Arnold Ventures, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from AbbVie, America's Health Insurance Plans, Anthem, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Humana, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Sun Life Financial, uniQure, and United Healthcare. Agboola, Nikitin, and Pearson are employed by ICER. Through their affiliated institutions, Tice, Touchette, and Lien received funding from ICER for the work described in this summary.
本摘要的资助方为 Arnold Ventures、Donaghue 基金会、哈佛朝圣者健康保健和 Kaiser 基金会健康计划，他们为独立组织临床与经济评价研究所（ICER）提供了资金，该组织评估医疗干预措施的价值证据。ICER 的年度政策峰会由 AbbVie、美国健康保险计划协会、Anthem、Alnylam、阿斯利康、Biogen、加州蓝盾、勃林格殷格翰、Cambia 健康服务、CVS、Editas、Evolve 药房、Express Scripts、基因泰克/罗氏、葛兰素史克、哈佛朝圣者、医疗保健服务公司、HealthFirst、Health Partners、Humana、强生（杨森）、Kaiser 永久、利奥制药、美纳里克斯、默克、诺华、国家制药理事会、辉瑞、Premera、Prime 治疗学、再生元、赛诺菲、太阳生活金融、uniQure 和 United Healthcare 提供支持。Agboola、Nikitin 和 Pearson 受雇于 ICER。通过他们的附属机构，Tice、Touchette 和 Lien 从 ICER 获得了资金，用于开展本摘要中所描述的工作。
